Mgc Pharmaceuticals Stock Revenue
MGC Pharmaceuticals fundamentals help investors to digest information that contributes to MGC Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of MGC OTC Stock. The fundamental analysis module provides a way to measure MGC Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MGC Pharmaceuticals otc stock.
MGC |
MGC Pharmaceuticals OTC Stock Revenue Analysis
MGC Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current MGC Pharmaceuticals Revenue | 4.65 M |
Most of MGC Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MGC Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, MGC Pharmaceuticals reported 4.65 M of revenue. This is 99.94% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The revenue for all United States stocks is 99.95% higher than that of the company.
MGC Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MGC Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of MGC Pharmaceuticals could also be used in its relative valuation, which is a method of valuing MGC Pharmaceuticals by comparing valuation metrics of similar companies.MGC Pharmaceuticals is currently under evaluation in revenue category among its peers.
MGC Fundamentals
| Return On Equity | -2.19 | |||
| Return On Asset | -0.45 | |||
| Operating Margin | (3.28) % | |||
| Current Valuation | 24.97 M | |||
| Shares Outstanding | 2.87 B | |||
| Shares Owned By Insiders | 9.10 % | |||
| Shares Owned By Institutions | 6.12 % | |||
| Price To Book | 5.69 X | |||
| Price To Sales | 5.81 X | |||
| Revenue | 4.65 M | |||
| Gross Profit | 562.87 K | |||
| EBITDA | (16.44 M) | |||
| Net Income | (20.35 M) | |||
| Cash And Equivalents | 1.89 M | |||
| Total Debt | 4.35 M | |||
| Debt To Equity | 0.84 % | |||
| Current Ratio | 0.84 X | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (12.16 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 16 | |||
| Beta | 1.23 | |||
| Market Capitalization | 17.2 M | |||
| Total Asset | 22.6 M | |||
| Z Score | 1.8 | |||
| Net Asset | 22.6 M |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in MGC OTC Stock
If you are still planning to invest in MGC Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MGC Pharmaceuticals' history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |